Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy
- PMID: 11929817
Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy
Abstract
Recent studies indicate that continuous administration improves the antitumoral efficacy of angiogenesis inhibitors, as compared with intermittent dosing, suggesting a potential role of gene therapy in antiangiogenic tumor therapy. We established a tissue-engineered implant system for the continuous in vivo production of thrombospondin-2 (TSP-2), a potent endogenous inhibitor of tumor growth and angiogenesis. Fibroblasts were retrovirally transduced to overexpress TSP-2 and were seeded onto biodegradable polymer scaffolds. After transplantation into the peritoneal cavity of nude mice, bioimplants maintained high levels of TSP-2 secretion over extended time periods, resulting in increased levels of circulating TSP-2. Bioimplant-generated TSP-2 potently inhibited tumor growth and angiogenesis of human squamous cell carcinomas, malignant melanomas, and Lewis lung carcinomas that were implanted at a distant site. These results provide the first proof-of-principle for the feasibility and therapeutic efficiency of systemic, cell-based antiangiogenic gene therapy using biodegradable polymer grafts for the treatment of cancer.
Similar articles
-
Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis.Gene Ther. 2004 May;11(9):739-45. doi: 10.1038/sj.gt.3302219. Gene Ther. 2004. PMID: 15103317
-
A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer.Cancer Gene Ther. 2000 Apr;7(4):589-96. doi: 10.1038/sj.cgt.7700147. Cancer Gene Ther. 2000. PMID: 10811477
-
Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen.Mol Ther. 2006 Aug;14(2):175-82. doi: 10.1016/j.ymthe.2006.01.017. Epub 2006 Apr 5. Mol Ther. 2006. PMID: 16600689
-
Progress in antiangiogenic gene therapy of cancer.Cancer. 2000 Sep 15;89(6):1181-94. Cancer. 2000. PMID: 11002212 Review.
-
Tumor progression: the effects of thrombospondin-1 and -2.Int J Biochem Cell Biol. 2004 Jun;36(6):1038-45. doi: 10.1016/j.biocel.2004.01.008. Int J Biochem Cell Biol. 2004. PMID: 15094119 Review.
Cited by
-
Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.Cold Spring Harb Perspect Med. 2012 May;2(5):a006627. doi: 10.1101/cshperspect.a006627. Cold Spring Harb Perspect Med. 2012. PMID: 22553494 Free PMC article. Review.
-
Whole blueberry powder modulates the growth and metastasis of MDA-MB-231 triple negative breast tumors in nude mice.J Nutr. 2011 Oct;141(10):1805-12. doi: 10.3945/jn.111.140178. Epub 2011 Aug 31. J Nutr. 2011. PMID: 21880954 Free PMC article.
-
Molecular regulation of tumor angiogenesis and perfusion via redox signaling.Chem Rev. 2009 Jul;109(7):3099-124. doi: 10.1021/cr8005125. Chem Rev. 2009. PMID: 19374334 Free PMC article. Review. No abstract available.
-
Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.Adv Drug Deliv Rev. 2016 Feb 1;97:56-68. doi: 10.1016/j.addr.2015.12.016. Epub 2016 Jan 4. Adv Drug Deliv Rev. 2016. PMID: 26763408 Free PMC article. Review.
-
Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties.Cancer Sci. 2006 Dec;97(12):1315-20. doi: 10.1111/j.1349-7006.2006.00336.x. Epub 2006 Oct 9. Cancer Sci. 2006. PMID: 17032310 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous